Seeking Alpha

Recent Phase III study results published in the New England Journal of Medicine show Novartis'...

Recent Phase III study results published in the New England Journal of Medicine show Novartis' (NVS) drug canakinumab significantly relieves symptoms in patients with a serious form of childhood arthritis. The drug was assessed in two trials and both showed canakinumab provided substantial symptom relief and delayed disease flare recurrence, thus allowing patients to substantially reduce or discontinue use of corticosteroids.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)